These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 16712904

  • 1. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
    Cimenti C, Koestenberger M, Leschnik B, Haidl H, Muntean W.
    Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time.
    Koestenberger M, Cvirn G, Gallistl S, Muntean W.
    Blood Coagul Fibrinolysis; 2004 Oct; 15(8):693-7. PubMed ID: 15613925
    [Abstract] [Full Text] [Related]

  • 4. Drotrecogin alfa (activated, Xigris) in combination with heparin or melagatran: an in vitro investigation.
    Koestenberger M, Cvirn G, Gallistl S, Baier K, Leschnik B, Muntean W.
    J Thromb Thrombolysis; 2004 Aug; 18(1):5-10. PubMed ID: 15744547
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates.
    Gruber A, Carlsson S, Kotzé HF, Marzec U, Sarich TC, Hanson SR.
    Thromb Res; 2007 Aug; 119(1):121-7. PubMed ID: 16448687
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
    Boström SL, Hansson GF, Sarich TC, Wolzt M.
    Thromb Res; 2004 Aug; 113(1):85-91. PubMed ID: 15081569
    [Abstract] [Full Text] [Related]

  • 14. Effects of recombinant human activated protein C on the coagulation system: a study with rotational thromboelastometry.
    Nilsson CU, Hellkvist PD, Engström M.
    Acta Anaesthesiol Scand; 2008 Oct; 52(9):1246-9. PubMed ID: 18823464
    [Abstract] [Full Text] [Related]

  • 15. A step change in oral anticoagulation: lack of coagulation monitoring with ximelagatran.
    Carlsson SC, Schulman S.
    Semin Vasc Med; 2005 Aug; 5(3):259-65. PubMed ID: 16123913
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study.
    Kuhle S, Lau A, Bajzar L, Vegh P, Halton J, Cherrick I, Anderson R, Desai S, McCusker P, Wu J, Abshire T, Mahoney D, Mitchell L.
    Br J Haematol; 2006 Sep; 134(5):526-31. PubMed ID: 16856890
    [Abstract] [Full Text] [Related]

  • 17. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate.
    Cosmi B, Agnelli G, Young E, Hirsh J, Weitz J.
    Thromb Haemost; 1993 Sep 01; 70(3):443-7. PubMed ID: 8259546
    [Abstract] [Full Text] [Related]

  • 18. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
    Semeraro F, Piro D, Rossiello MR, Ammollo T, Colucci M.
    Thromb Haemost; 2007 Dec 01; 98(6):1208-14. PubMed ID: 18064315
    [Abstract] [Full Text] [Related]

  • 19. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
    Mattsson C, Menschiek-Lundin A, Wåhlander K, Lindahl TL.
    Thromb Haemost; 2001 Aug 01; 86(2):611-5. PubMed ID: 11522011
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.